{"id":654413,"date":"2023-06-06T11:08:02","date_gmt":"2023-06-06T11:08:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654413"},"modified":"2023-06-06T11:08:02","modified_gmt":"2023-06-06T11:08:02","slug":"tinea-pedis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-glaxosmithkline-novartis-south-end-skin-care-taro-pharma-medicis-global","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tinea-pedis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-glaxosmithkline-novartis-south-end-skin-care-taro-pharma-medicis-global_654413.html","title":{"rendered":"Tinea Pedis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline, Novartis, South End Skin Care, Taro Pharma, Medicis Global"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1685987084.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Tinea Pedis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline, Novartis, South End Skin Care, Taro Pharma, Medicis Global\" src=\"https:\/\/www.abnewswire.com\/uploads\/1685987084.jpeg\" alt=\"Tinea Pedis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline, Novartis, South End Skin Care, Taro Pharma, Medicis Global\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cTinea Pedis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Tinea Pedis.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Tinea Pedis Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Tinea Pedis, historical and forecasted epidemiology as well as the Tinea Pedis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Tinea Pedis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tinea-pedis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Tinea Pedis Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Tinea Pedis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Tinea Pedis market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>The skin between the toes of the feet may become white and wet, the soles may become dry and flaky, or the skin may become reddened and blistered throughout the entire foot<\/li>\n<li>According to data from Omics,<strong> 1.5%<\/strong> of all valve diseases are prevalent in Japan. Athlete&#8217;s foot is seen in 1.0% of people with fungal illness.<strong> 2.0%<\/strong> of individuals older than 75 years have moderate or severe aortic stenosis<\/li>\n<li><strong>Key Tinea Pedis Companies:<\/strong> Taro Pharmaceuticals, Mylan Inc., Encube Ethicals Pvt. Ltd., Bausch &amp; Lomb Incorporated, GlaxoSmithKline, South End Skin Care, Taro Pharmaceuticals,, Medicis Global Service Corporation, Almirall, S.A., Novartis, Tinea Pharmaceuticals, Therapeutics, Inc., and others<\/li>\n<li><strong>Key Tinea Pedis Therapies:<\/strong> TA103, Econazole Nitrate Cream, Ketoconazole Cream, Omeprazole, W0027, Terbinafine Hydrochloride, Oxiconazole, 33525, LAS41003, Terbinafine, Luliconazole Cream, UHE-103A1 cream, and others<\/li>\n<li>The Tinea Pedis epidemiology based on gender analyzed that it can be estimated that Tinea Pedis is more common in males than female<\/li>\n<li>The Tinea Pedis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tinea Pedis pipeline products will significantly revolutionize the Tinea Pedis market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Tinea Pedis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Tinea Pedis, also known as tinea pedis, is a fungal infection that affects the skin and foot. Although any part of the foot can be impacted by tinea pedis, this infection most frequently affects the area in between the toes. Skin fissures or scales that might be red and irritating are frequently signs of tinea pedis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Tinea Pedis Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tinea-pedis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/tinea-pedis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Tinea Pedis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Tinea Pedis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Tinea Pedis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Tinea Pedis<\/li>\n<li>Prevalent Cases of Tinea Pedis by severity<\/li>\n<li>Gender-specific Prevalence of Tinea Pedis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Tinea Pedis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Tinea Pedis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tinea-pedis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Tinea Pedis Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Tinea Pedis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tinea Pedis market or expected to get launched during the study period. The analysis covers Tinea Pedis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Tinea Pedis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Tinea Pedis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TA103:<\/strong> Taro Pharmaceuticals<\/li>\n<li><strong>Econazole Nitrate Cream:<\/strong> Mylan Inc.<\/li>\n<li><strong>Ketoconazole Cream:<\/strong> Encube Ethicals Pvt. Ltd.<\/li>\n<li><strong>Omeprazole:<\/strong> Bausch &amp; Lomb Incorporated<\/li>\n<li><strong>W0027:<\/strong> GlaxoSmithKline<\/li>\n<li><strong>Terbinafine Hydrochloride:<\/strong> South End Skin Care<\/li>\n<li><strong>Oxiconazole:<\/strong> Taro Pharmaceuticals<\/li>\n<li><strong>33525:<\/strong> Medicis Global Service Corporation<\/li>\n<li><strong>LAS41003:<\/strong> Almirall, S.A.<\/li>\n<li><strong>Terbinafine:<\/strong> Novartis<\/li>\n<li><strong>Luliconazole Cream:<\/strong> Tinea Pharmaceuticals<\/li>\n<li><strong>UHE-103A1 cream:<\/strong> Therapeutics, Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Tinea Pedis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tinea-pedis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Tinea Pedis Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Tinea Pedis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Tinea Pedis Companies:<\/strong> Taro Pharmaceuticals, Mylan Inc., Encube Ethicals Pvt. Ltd., Bausch &amp; Lomb Incorporated, GlaxoSmithKline, South End Skin Care, Taro Pharmaceuticals,, Medicis Global Service Corporation, Almirall, S.A., Novartis, Tinea Pharmaceuticals, Therapeutics, Inc., and others<\/li>\n<li><strong>Key Tinea Pedis Therapies:<\/strong> TA103, Econazole Nitrate Cream, Ketoconazole Cream, Omeprazole, W0027, Terbinafine Hydrochloride, Oxiconazole, 33525, LAS41003, Terbinafine, Luliconazole Cream, UHE-103A1 cream, and others<\/li>\n<li><strong>Tinea Pedis Therapeutic Assessment:<\/strong> Tinea Pedis current marketed and Tinea Pedis emerging therapies<\/li>\n<li><strong>Tinea Pedis Market Dynamics:<\/strong> Tinea Pedis market drivers and Tinea Pedis market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Tinea Pedis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Tinea Pedis Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Tinea Pedis companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tinea-pedis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Tinea Pedis Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Tinea Pedis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Tinea Pedis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Tinea Pedis<\/p>\n<p style=\"text-align: justify;\">4. Tinea Pedis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Tinea Pedis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Tinea Pedis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Tinea Pedis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Tinea Pedis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Tinea Pedis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Tinea Pedis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Tinea Pedis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Tinea Pedis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Tinea Pedis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Tinea Pedis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Tinea Pedis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Tinea Pedis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Tinea Pedis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Tinea Pedis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tinea-pedis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-glaxosmithkline-novartis-south-end-skin-care-taro-pharma-medicis-global\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tinea-pedis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-glaxosmithkline-novartis-south-end-skin-care-taro-pharma-medicis-global\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cTinea Pedis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Tinea Pedis. DelveInsight&rsquo;s &ldquo;Tinea Pedis Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Tinea Pedis, historical and forecasted epidemiology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tinea-pedis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-glaxosmithkline-novartis-south-end-skin-care-taro-pharma-medicis-global_654413.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-654413","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=654413"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654413\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=654413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=654413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=654413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}